Clinical trials: Overweight or Obese Adults
Metabolic Disease
Resistance Exercise, Metabolism and Time of Day
The aim of the current study is to determine the effect of time of day on the muscle and metabolic responses to resistance exercises in obese or overweight adults. To achieve this aim we have the following objectives: 1.
- Trial name
- NCT05321914
- Testing
- Exercise training
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Glasgow
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
- Trial name
- NCT07399678
- Testing
- ALV-100
- Where
- 3 sites in United States
- Volunteers
- 180 people
- Sponsor
- Alveus Therapeutics, Inc.
Mediterranean Diet, Overweight or Obese Adults
ENERGY2MOB STUDY: OBESITY MANAGEMENT IN BERGUEDÀ
Background: Obesity is a prevalent multifactorial disease worldwide and has become a significant public health concern. The latest data from the 2022 Catalonia Health Survey show that 56.2% of men and 43.7% of women are…
- Conditions
- Mediterranean Diet, Overweight or Obese Adults, Exercise Therapy, Cardiovascular Diseases
- Trial name
- ENERGY2MOB (NCT06988904)
- Testing
- Energy2MOB
- Where
- Spain
- Volunteers
- 136 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Apnea, Sleep Disorders
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive…
- Conditions
- Apnea, Sleep Disorders, Overweight and/or Obesity
- Trial name
- NCT07823608
- Testing
- Berobenatide
- Where
- 6 sites in United States
- Volunteers
- 258 people
- Sponsor
- Pfizer
Obesity or Overweight
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 1 (NCT07784725)
- Testing
- AZD6234
- Where
- 212 sites in United States, Argentina and 14 more
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Obesity or Overweight, Weight-Related Comorbidity
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.
- Conditions
- Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
- Trial name
- SELENE 3 (NCT07776509)
- Testing
- Lenbelintide
- Where
- 96 sites in United States, Argentina and 9 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Obesity, Type 2 Diabetes Mellitus (T2DM)
MagDI Italian Study
The objective of the MagDI Italy Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side…
- Conditions
- Obesity, Type 2 Diabetes Mellitus (T2DM), Anastomosis
- Trial name
- NCT06613711
- Testing
- Magnet System, DI Biofragmentable
- Where
- 4 sites in Italy
- Volunteers
- 27 people
- Sponsor
- GT Metabolic Solutions, Inc.
Obesity, Overweight
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- NCT07654361
- Testing
- Aleniglipron
- Where
- 71 sites in United States
- Volunteers
- 3,600 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obese, Weight Loss
Effects of Adding L-BAIBA or L-BAIBA + Grains of Paradise to Exercising Adult Overweight and Obese Men and Women
The goal of this intervention study is to examine changes in body composition, weight loss, and cardio-metabolic risk factors after adding supplementation of L-Beta aminoisobutyric acid (L-BAIBA) and Grains of Paradise to…
- Conditions
- Obese, Weight Loss, Body Weight, Cardiometabolic Syndrome
- Trial name
- GOP (NCT05775003)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Lindenwood University
Overweight, Obesity
A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in…
- Trial name
- NCT07665879
- Testing
- Eloralintide
- Where
- 2 sites in Germany, Sweden
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity and Obesity-related Medical Conditions
Efficacy and Safety of Tirzepatide for Weight Management
The goal of this study is to learn if tirzepatide helps people manage their weight safely. It will include adults in Bangladesh who are overweight or obese, with or without type 2 diabetes.
- Trial name
- NCT06918405
- Testing
- Tirzepatide
- Where
- Bangladesh
- Volunteers
- 440 people
- Sponsor
- Chittagong Medical College
Healthy Participants, Obesity
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or…
- Trial name
- NCT07511205
- Testing
- AZD1043
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity/Overweight in Adult
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
This study is a multicenter, randomized, open-label, parallel-group phase III clinical trial comparing the efficacy and safety of GZR18 Injection and semaglutide (Wegovy®) in adult obese or overweight subjects, aiming to evaluate…
- Trial name
- NCT07150975
- Testing
- GZR18, Semaglutide(Wegovy® )
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Overweight or Obesity; Type 2 Diabetes, Weight Loss Maintenance
AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)
This is a randomized controlled trial to compare the effect of AI-assisted multi-domain lifestyle and continued tirzepatide on body weight loss maintenance.
- Trial name
- NCT07555730
- Testing
- AI assisted multi-domain lifestyle intervention, Tirzepatide
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Huazhong University of Science and Technology
Mobility Limitation, Overweight or Obesity
Functional Fitness for Overweight or Obese Adults With Mobility Disabilities
Over 64 million people in the U.S. have a permanent disability, with mobility-related disability (MRD) representing the most prevalent disability type (13.7%).
- Conditions
- Mobility Limitation, Overweight or Obesity, Physical Disability
- Trial name
- COBRE Pilot (NCT05880966)
- Testing
- Functional Fitness
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Kansas
Obesity, Overweight
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM.
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
- Trial name
- NCT07654374
- Testing
- aleniglipron
- Where
- 74 sites in United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity and Overweight, Diabetes Mellitus
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
The goal of this clinical trial is to learn the best combination of family components that yields optimal weight loss among Black adults.
- Conditions
- Obesity and Overweight, Diabetes Mellitus, Weight Loss, Behavior Change
- Trial name
- FAM WEL B-ing (NCT06724406)
- Testing
- Family Skills Training Session Quantity: 5, Family Skills Training Session Mode: In-person, Family Skills Training Content: Communication
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- University of North Carolina, Chapel Hill
Overweight, Obesity
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily.
- Trial name
- OASIS 4 (NCT05564117)
- Testing
- Semaglutide
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 307 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year.
- Trial name
- NCT06683508
- Testing
- LY3549492
- Where
- 49 sites in United States
- Volunteers
- 288 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo).
- Trial name
- OASIS 5 (NCT07770841)
- Testing
- Semaglutide
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 450 people
- Sponsor
- Novo Nordisk A/S